FilingSEC EDGAR8-K
Century Therapeutics Presents Nonclinical Data for Type 1 Diabetes Candidate CNTY-813
· SEC accepted
StageNonclinical
Filing content
Century Therapeutics presented nonclinical data for its type 1 diabetes candidate CNTY-813 at the EASD meeting. The company remains on track to submit an IND in the fourth quarter of 2026.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…